Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide.
Despite developments in therapeutic approaches for the past few decades, the 5-year …

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with
potential to provide greater clinical benefit to patients with advanced-stage cancer. In …

Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis.
However, their aberrant overexpression and glycosylation in various malignancies facilitate …

Previously, clinical approaches to using the immune system against cancer focused on
vaccines that intended to specifically initiate or amplify a host response against evolving …

Elucidating the spectrum of epithelial-mesenchymal transition (EMT) and mesenchymal-
epithelial transition (MET) states in clinical samples promises insights on cancer progression …

Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer
(NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet …